Considering the time to progression as metastatic disease (from the detection of primary CRC to the diagnosis of first distant metastasis, TTPM), the occurrence of BRAF mutations again remained a statistically-independent negative prognostic factor [p = 0.009; HR: 2.97; 95 % CI: 1.26–6.33] (Table 3). The gene discussed is BRAF; the disease is metastatic neoplasm.